Oster H, Mittelman M. Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall. haematol [Internet]. 2020Sep.10 [cited 2026Feb.6];. Available from: https://haematologica.org/article/view/13117